LARGO, Fla., June 21 /PRNewswire-FirstCall/ -- GeoPharma, Inc. , a fast-growing drug development and manufacturing company specialized in unique generic drugs, antibiotics, and health products, announced today that Dr. R. Vijay, M.D., F.A.C.S, has accepted an appointment to its Scientific Advisory Board and agreed to be the company's Chief Medical Advisor and Officer of Government Liaison. Dr. Vijay is a distinguished cardiovascular and thoracic surgeon, researcher, proven leader of the medical community and also a member of the Advisory Committee to the Director, National Institute of Health (NIH). Dr. Vijay will be adding other members to GeoPharma's Scientific Advisory Board that will include eminent scientists and medical professionals.
Dr. Vijay received his medical degree from the University of Bombay in 1964 and did his residency and fellowships at Fordham-Misericordial Hospital, VA Hospital and Montefiore Hospital, Bronx, NY from 1965 to 1972. He has been practicing cardiovascular and thoracic surgery in Tampa, Florida. He has initiated and performed Florida's first heart transplant surgery, initiated open-heart surgery program in Tampa and has built one of the largest heart transplant programs in the country. He authored over 50 publications in medical journals. He also has been appointed as Chairman of the Florida Board of Medicine and member of several committees including State Organ Transplant Council. He is founder and president of the Association of American Physicians from South Asia, and Chairman of the Association of American Physicians from India Charitable Foundation and the Indian American Republican Council.
Dr. Vijay stated, "I visited GeoPharma's manufacturing plants in Largo and also the antibiotic plant at Baltimore, met the executive team and am convinced about the company's strategic plans." He also added, "I will be glad to bring my expertise to the team and help accelerate their progress."
"Since we are working on certain unique drug projects beyond routine ANDAs, Dr. Vijay's experience, knowledge and physician-researcher perspective will add a valuable dimension to our research projects," stated Dr. Kotha Sekharam, President of GeoPharma.
GeoPharma, Inc. is a rapidly growing pharmaceutical company specializing in the manufacturing and distribution of over-the-counter, nutritional, generic drug and functional food products. The company's growth strategy is to capitalize on its manufacturing expertise to develop high-margin generic or novel drugs for niche markets with high barriers to entry. GeoPharma's competitive advantage lies in its ability to circumvent or overcome the challenges in these markets. For more about GeoPharma, Inc., go to our websites at http://www.geopharmainc.com , http://www.onlineihp.com and http://www.carbslim.com .
This press release may contain statements, which constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those regarding the company and its subsidiaries' expectations, intentions, strategies and beliefs pertaining to future performance. All statements contained herein are based upon information available to the company's management as of the date hereof, and actual results may vary based upon future events, both within and without management's control. Important factors that could cause such differences are described in the company's periodic filings with the Securities and Exchange Commission.
GeoPharma, Inc.CONTACT: Carol Dore-Falcone, VP-CFO, GeoPharma, Inc., +1-727-544-8866,ext. 244, or cdf@onlineihp.com
